Publication | Closed Access

Maleimide as the PEG end-group promotes macrophage-targeted drug delivery of PEGylated nanoparticles in vivo by enhancing interaction with circulating erythrocytes

NanoparticlesNanomedicineCell-based Drug DeliveryDrug TargetingEngineeringImmunologyNano-drug DeliveryBiomedical EngineeringPegylated Nanoparticles